Last reviewed · How we verify
NCO-48 Fumarate
NCO-48 Fumarate is a Small molecule drug developed by Nucorion Pharmaceuticals, Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | NCO-48 Fumarate |
|---|---|
| Sponsor | Nucorion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B (PHASE1)
- Safety, Tolerability and Pharmacokinetics of NCO-48 Fumarate in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NCO-48 Fumarate CI brief — competitive landscape report
- NCO-48 Fumarate updates RSS · CI watch RSS
- Nucorion Pharmaceuticals, Inc. portfolio CI
Frequently asked questions about NCO-48 Fumarate
What is NCO-48 Fumarate?
NCO-48 Fumarate is a Small molecule drug developed by Nucorion Pharmaceuticals, Inc..
Who makes NCO-48 Fumarate?
NCO-48 Fumarate is developed by Nucorion Pharmaceuticals, Inc. (see full Nucorion Pharmaceuticals, Inc. pipeline at /company/nucorion-pharmaceuticals-inc).
What development phase is NCO-48 Fumarate in?
NCO-48 Fumarate is in Phase 1.
Related
- Manufacturer: Nucorion Pharmaceuticals, Inc. — full pipeline
- Compare: NCO-48 Fumarate vs similar drugs
- Pricing: NCO-48 Fumarate cost, discount & access